Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a paper by Scott Kopetz et al. on X:
“Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer:
- BREAKWATER Phase 3 trial
- ORR 60% vs. 40.0%
- DoR 13.9 vs. 11.1 months
- OS NE vs. 14.6 months
New SOC for BRAF mutant CRC”
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Authors: Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Singh Wasan, Jayesh Desai, Fortunato Ciardiello, Rona Yaeger, Timothy S. Maughan, Elena Beyzarov, Xiaoxi Zhang, Graham Ferrier, Xiaosong Zhang & Josep Tabernero
